
Phaarmasia Ltd is Rated Hold by MarketsMOJO
2025-12-25 15:12:04Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 18 Nov 2025. While the rating change occurred then, the analysis and financial metrics discussed here reflect the company's current position as of 25 December 2025, providing investors with an up-to-date view of its fundamentals, returns, and market standing.
Read More
Phaarmasia Hits New 52-Week High of Rs.108.41, Marking Strong Momentum
2025-12-24 10:36:45Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.108.41 today, underscoring a remarkable rally that has captured market attention. This milestone reflects sustained momentum as the stock continues to trade above all major moving averages.
Read More
Phaarmasia Hits New 52-Week High at Rs.106.29 Marking Strong Momentum
2025-12-23 11:17:14Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.106.29 today, reflecting sustained momentum and a remarkable rally over the past several weeks.
Read More
Phaarmasia Reaches New 52-Week High of Rs.104.21 Marking Significant Rally
2025-12-22 11:36:36Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, has attained a new 52-week high of Rs.104.21, underscoring a remarkable rally that has captured market attention. This milestone reflects sustained momentum driven by consistent gains over the past three weeks and a notable outperformance relative to its sector peers.
Read More
Phaarmasia Hits New 52-Week High of Rs.102.17 Marking Strong Momentum
2025-12-19 11:17:38Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.102.17 today, underscoring a remarkable rally that has captured market attention. This milestone reflects sustained momentum driven by consistent gains over the past three weeks and a notable outperformance relative to its sector peers.
Read More
Phaarmasia Hits New 52-Week High of Rs.100.17, Marking Strong Momentum
2025-12-18 11:13:34Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.100.17 today, underscoring a remarkable rally that has captured market attention. The stock’s sustained upward trajectory over the past three weeks highlights significant momentum within the sector.
Read More
Phaarmasia Hits New 52-Week High of Rs.98.22, Marking Strong Momentum
2025-12-17 11:23:05Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.98.22 today, underscoring a sustained rally that has captured market attention. The stock’s performance over the past 21 trading sessions reflects a remarkable upward trajectory, significantly outpacing sector benchmarks and broader market indices.
Read More
Phaarmasia Hits New 52-Week High of Rs.96.3, Marking Strong Momentum
2025-12-16 10:41:58Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.96.3 today, underscoring a sustained rally that has propelled the stock well above its previous levels. This milestone reflects notable momentum in the stock’s performance over recent weeks.
Read More
Phaarmasia Hits New 52-Week High of Rs.94.42 Marking Strong Momentum
2025-12-15 11:17:56Phaarmasia, a key player in the Pharmaceuticals & Biotechnology sector, reached a fresh 52-week high of Rs.94.42 today, underscoring a remarkable rally that has seen the stock gain over 182% in the past 21 trading sessions.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2025 | Source : BSENewspaper Publication of the Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2025.
Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2025
14-Nov-2025 | Source : BSESubmission of Unaudited Financial Results for the Quarter and Half Year Ended 30th September 2025
Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2025
14-Nov-2025 | Source : BSESubmission of Unaudited Financial results for the Quarter and Half Year Ended 30th September 2025
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






